Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men.
Abstract
Background Data concerning the relation between antiphospholipid (aPL) antibodies and myocardial infarction in subjects without evidence of overt autoimmune disease are conflicting. All published studies have been performed on survivors of myocardial infarction or in patients with established coronary heart disease. The purpose of the present study was to determine whether the presence of aPL antibodies, namely, anti-cardiolipin (aCL) antibodies, carries a risk for myocardial infarction in a prospective cohort. Methods and results The sera to be studied were drawn at entry from middle-aged dyslipidemic men (non-high-density lipoprotein cholesterol, > or = 5.2 mmol/L) participating in the Helsinki Heart Study, a 5-year coronary primary prevention trial with gemfibrozil. Samples were tested for IgG-class antibodies to cardiolipin by an ELISA. The risk was estimated with logistic regression analysis using a nested case-control design with 133 patients (myocardial infarction or cardiac death) and 133 control subjects, matched for treatment (gemfibrozil/placebo) and geographical area. The aCL antibody level, as expressed in optical density units, was significantly higher in patients than in control subjects (0.417 versus 0.361; P Conclusions In a prospective cohort of healthy middle-aged men, the presence of a high aCL antibody level is an independent risk factor for myocardial infarction or cardiac death. Antibodies to cardiolipin and oxidized LDL may, at least in part, represent…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Retrospective, case-control and cross-sectional studies with different designs, patient selection criteria, aPL profiles and risk factors have produced contradictory results.
“Retrospective, [1][2][3][4] case-control [5][6][7][8][9][10][11][12] and cross-sectional 13,14 studies with different designs, patient selection criteria, aPL profiles and risk factors have produced contradictory results.”
From Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. (2011) · cites this paper as [8]
Cites
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · see citing works
Self-citationAnticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis
Ginsburg, K. S., Liang, M. H., Newcomer, L., Goldhaber, S. Z., Schur, P. H., Hennekens, C. H., & Stampfer, M. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-997 · Cited by 526 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 974 · see citing works
Diagnosis and management of the antiphospholipid syndrome
Garcia, D., & Erkan, D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705454 · Cited by 819 · see citing works
Urbanus, R. T., Siegerink, B., Roest, M., Rosendaal, F. R., de Groot, P. G., & Algra, A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70239-x · Cited by 429 · see citing works
Schoenfeld, S. R., Kasturi, S., & Costenbader, K. H. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.12.002 · Cited by 370 · see citing works
Ruffatti, A., Del Ross, T., Ciprian, M., Bertero, M. T., Salvatore, S., Scarpato, S., Montecucco, C., Rossi, S., Caramaschi, P., Biasi, D., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.142042 · Cited by 184 · see citing works
F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases
Praticò, D., Rokach, J., Lawson, J., & FitzGerald, G. A. (2004) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2003.09.012 · Cited by 120 · see citing works
Vikerfors, A., Johansson, A.-B., Gustafsson, J. T., Jonsen, A., Leonard, D., Zickert, A., Nordmark, G., Sturfelt, G., Bengtsson, A., Ronnblom, L., et al. (2013) · Rheumatology · doi:10.1093/rheumatology/kes252 · Cited by 51 · see citing works
- Authors
- Vaarala, O., Mänttäri, M., Manninen, V., Tenkanen, L., Puurunen, M., Aho, K., & Palosuo, T.
- Affiliations
- University of Helsinki (FI)
- From the National Public Health Institute (O.V., M.P., K.A., T.P.); and the First Department of Medicine (M.M., V.M., L.T.), University of Helsinki, Finland.
- ORCID
- Puurunen, Marja
- Venue
- Circulation
- Published
- 1995-01
- Volume
- 91
- Issue
- 1
- Pages
- 23-27
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2065122382
- Cited by
- 317
- References
- 2
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 7 · 2018: 5 · 2017: 8 · 2016: 5 · 2015: 6 · 2014: 5 · 2013: 10 · 2012: 12
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- anticardiolipin antibodies, antiphospholipid antibodies, myocardial infarction, cardiovascular mortality, dyslipidemia, oxidized LDL antibodies, atherosclerotic cardiovascular risk, middle-aged men, gemfibrozil, cross-reactive antibodies, primary prevention
- MeSH terms
- Double-Blind Method, Humans, Lipoproteins, LDL, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Risk Factors, Smoking, Triglycerides, Biomarkers, Case-Control Studies, Antibodies, Anticardiolipin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
